Kura Oncology (NASDAQ: KURA)
Kura Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kura Oncology Company Info
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
News & Analysis
Why Kura Oncology Stock Is Sliding Today
A partial clinical hold for the company's experimental leukemia treatment is making investors nervous.
Why Kura Oncology Is Skyrocketing Today
Kura Oncology is riding the coattails of another clinical-stage biopharmaceutical company.
3 Beaten-Down Biotech Stocks: Can They Bounce Back?
See if these oncology-driven drugmakers have what it takes to recover from recent setbacks.
Here's Why Kura Oncology Fell Today
The biotech's drug works -- just not on as many people as investors would have hoped for.
Valuation
Earnings Transcripts
Kura Oncology, inc (KURA) Q3 2021 Earnings Call Transcript
KURA earnings call for the period ending September 30, 2021.
Kura Oncology, inc (KURA) Q2 2021 Earnings Call Transcript
KURA earnings call for the period ending June 30, 2021.
Kura Oncology, Inc. (KURA) Q1 2021 Earnings Call Transcript
KURA earnings call for the period ending March 31, 2021.
Kura Oncology, Inc. (KURA) Q4 2020 Earnings Call Transcript
KURA earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.